PT003

PT003 is an early-stage investigational drug candidate being developed by PulmoSIM Therapeutics, a biopharmaceutical company focused on rare and progressive respiratory diseases. The candidate was identified using the company's proprietary Systems Integrative Medicine (SIM) platform, which utilizes artificial intelligence and machine learning (via VeriSIM Life's BIO-SIM technology) to predict drug behavior and repurpose existing compounds for new therapeutic applications. PT003 is currently in the 'Strategy' or early discovery phase of development. While the specific molecular target and primary indication have not been publicly disclosed, the candidate is part of a pipeline that prioritizes high-unmet-need pulmonary conditions such as pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF).